Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
34 hedge funds and large institutions have $1.58M invested in Sorrento Therapeutics, Inc. in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 187 closing their positions.
1,286% more call options, than puts
Call options by funds: $97K | Put options by funds: $7K
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
85% less funds holding
Funds holding: 221 → 34 (-187)
97% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 187
99% less capital invested
Capital invested by funds: $176M → $1.58M (-$175M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$3.38M |
| 2 |
CGA
Crescent Grove Advisors
Lake Forest,
Illinois
|
+$34.1K |
| 3 |
HNB
Huntington National Bank
Columbus,
Ohio
|
+$8.96K |
| 4 |
WRPWM
Werba Rubin Papier Wealth Management
San Jose,
California
|
+$8.96K |
| 5 |
GBWM
Granite Bay Wealth Management
Portsmouth,
New Hampshire
|
+$3.05K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$44.9M |
| 2 |
BlackRock
New York
|
-$34.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$26.2M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$7.89M |
| 5 |
BRF
B. Riley Financial
Los Angeles,
California
|
-$4.62M |
SRNE Hedge Fund Activity: Q1 2023 in Review
34 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q1 2023, worth a combined $1.58M — down 99% from $176M a quarter earlier.
Sellers outnumbered buyers: 187 funds closed out of SRNE and 5 opened new positions — a net loss of 182 holders — while 7 trimmed existing stakes and 3 added.
The largest buyer was Paloma Partners, opening a new position worth an estimated $3.38M. The largest seller was State Street, exiting entirely with an estimated $44.9M sold.
- 34 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q1 2023, down from 221 in Q4 2022.
- Funds reported $1.58M of Sorrento Therapeutics, Inc. stock for Q1 2023, down 99% quarter-over-quarter.
- 5 funds opened new Sorrento Therapeutics, Inc. positions in Q1 2023 and 187 closed out, a net change of -182 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q1 2023 was Paloma Partners, an estimated $3.38M added.
- The largest Sorrento Therapeutics, Inc. seller in Q1 2023 was State Street, an estimated $44.9M sold.
Based on aggregated 13F filings for Q1 2023.